EN 简
About CARsgen®
We focus on innovative CAR T-cell therapies

We are biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases.

Read More
image
image
Pipeline
Innovative and differentiated product pipeline

We develop innovative CAR-T technologies to empower the next generation pipeline products.

Read More
We have built an integrated cell therapy platform
image

THANK-uCAR®

Allogeneic CAR-T platform
image

CycloCAR®

Cytokine and Chemokine Loaded CAR
image

LADAR®

Local Action Driven by Artificial Receptor
News Center
2025-06-16
CARsgen Presents Results of GPRC5D CAR-T CT071 at EHA 2025
2025-06-02
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
2025-05-28
CARsgen’s Satri-cel Granted Priority Review by the NMPA
2025-05-23
CARsgen’s Satri-cel Abstract Available on ASCO Website
2025-05-15
CARsgen’s CT071 Abstract Published on EHA Website
2025-05-12
CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy